Stereotaxis to Report Second Quarter 2025 Financial Results on August 7, 2025

Rhea-AI Summary

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, will release its Q2 2025 financial results on August 7, 2025 after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss results and corporate developments.

Stereotaxis' technology has been utilized in treating over 150,000 patients globally across the United States, Europe, Asia, and other regions. The company specializes in developing robotic systems, instruments, and information solutions for interventional laboratories, focusing on enhancing physician care delivery with robotic precision and safety.

ST. LOUIS, July 23, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 second quarter on Thursday, August 7, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments.

What:	Stereotaxis second quarter 2025 financial results conference call
When:	Thursday, August 7, 2025, at 4:30 p.m. ET (1:30 p.m. PT)
Dial In Number:	To access the live call, dial 888-596-4144 (US and Canada) or 1-646-968-2525 (International) and give the participant pass code 1064613.
Webcast:	To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/.
Call Replay:	A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please click here.

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

Investor Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly Peery
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

FAQ

When will Stereotaxis (NYSE: STXS) report Q2 2025 earnings?

Stereotaxis will report Q2 2025 financial results on Thursday, August 7, 2025 after the U.S. financial markets close, followed by a conference call at 4:30 p.m. ET.

How can investors access Stereotaxis Q2 2025 earnings call?

Investors can access the call by dialing 888-596-4144 (US/Canada) or 1-646-968-2525 (International) with pass code 1064613, or via webcast at the investor relations section of Stereotaxis' website.

How many patients have been treated with Stereotaxis technology?

Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and other regions.

What is Stereotaxis (STXS) main business focus?

Stereotaxis is a pioneer and global leader in surgical robotics specializing in minimally invasive endovascular intervention, developing robotic systems, instruments, and information solutions for interventional laboratories.